HemostOD is a Swiss preclinical-stage healthcare company focused on developing a scalable and universal source of platelets produced ex vivo. Utilizing its proprietary bioreactor technology, HemostOD creates platelets in vitro from immortalized hematopoietic stem cells, eliminating the need for donors. This innovation aims to improve safety and availability, potentially transforming transfusion medicine by addressing the recurring shortages of platelets in medical care.